1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Copanlisib + riTUXimab for indolent NHL

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Protocol: Copanlisib + riTUXimab for indolent NHL

New Protocol: Copanlisib + riTUXimab for indolent NHL
Study:
  • Double-blind, randomized, placebo-controlled phase III trial (CHRONOS-3)
  • CD20+ indolent non-Hodgkin lymphoma relapsed after last anti-CD20 containing therapy
  • Copanlisib + riTUXimab vs. placebo + riTUXimab
Efficacy:
  • CR: 34% vs. 15%
  • ORR: 81% vs. 48%
  • Median DoR: 20.4 vs. 17.3 mos
  • Median PFS: 21.5 vs. 13.8 mos (HR: 0.52 [0.39-0.69])
  • OS @ 3yr: 83% vs. 81%
Safety:
  • Grade >=3 AEs: hyperglycemia (54% vs. 8%), hypertension (40% vs. 9%), neutropenia (16% vs. 12%), pneumonia (6% vs. 3%)

Lancet Oncol 2021; 22: 678–89

Matasar MJ, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

https://doi.org/10.1016/S1470-2045(21)00145-5

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More